Table 5.
Multivariate analysis using a Cox proportional hazards model for overall survival and progression free survival in ADCTA group patients.
| Variable | Overall survival | Progression-free survival | ||||
|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | |
| High CD45 | 0.09 | 0.968 | 0.365–2.241 | 0.75 | 1.132 | 0.478–2.557 |
| High CD4 | 0.76 | 1.139 | 0.490–2.651 | 0.9 | 1.059 | 0.455–2.461 |
| High CD8 | 0.31 | 1.55 | 0.667–3.601 | 0.36 | 1.489 | 0.640–3.461 |
| High PD-1 | 0.01** | 3.662 | 1.442–9.302 | 0.07 | 2.202 | 0.933–5.198 |
| High PD-1/CD8 | P < 0.001*** | 11.382 | 3.320–35.707 | 0.01* | 3.458 | 1.304–9.174 |
| Tumor PD-L1 expression | 0.1 | 0.354 | 0.103–1.219 | 0.248 | 0.528 | 0.178–1.563 |
| Sex (male) | 0.54 | 0.769 | 0.331–1.788 | 0.79 | 0.891 | 0.382–2.079 |
| Age (≥57) | P < 0.001*** | 10.888 | 2.916–44.428 | 0.03* | 2.805 | 1.092–7.207 |
| With R/T | 0.92 | 0.901 | 0.118–6.858 | 0.62 | 0.592 | 0.076–4.606 |
| With C/T (TMZ) | 0.89 | 1.064 | 0.437–2.590 | 0.8 | 0.894 | 0.372–2.146 |
| With GKS | 0.24 | 0.586 | 0.240–1.425 | 0.95 | 0.973 | 0.412–2.295 |
| Without CCRT | P < 0.01** | 3.799 | 1.516–9.516 | 0.04* | 2.491 | 1.034–5.999 |
| KPS (≥70) | 0.54 | 0.769 | 0.331–1.788 | 0.79 | 0.891 | 0.382–2.079 |
| Gross total tumor resection | 0.07 | 0.452 | 0.193–1.058 | 0.02* | 0.352 | 0.144–0.585 |
| Presence of IHD1 mutation | 0.24 | 0.051 | 0–6.964 | 0.291 | 0.036 | 0–17.356 |
| Methylguanine-DNA methyltransferase methylation | 0.929 | 0.951 | 0.319–2.838 | 0.627 | 0.762 | 0.255–2.281 |
*P < 0.05.
**P < 0.01.
***P < 0.001.
HR, hazard ratio; 95% CI, 95% confidence interval; R/T, radiotherapy; TMZ, temozolomide; GKS, gamma knife; CCRT, concurrent chemoradiotherapy; ADCTA, autologous dendritic cell/tumor antigen immunotherapy; KPS, Karnofsky Performance Score; tumor location: T, temporal; F, frontal; O, occipital; P, parietal.